Abstract The liver is a common site of malignant disease with hepatocellular carcinoma and liver metastases accounting for the majority of liver malignancies. Conventional treatment options are confined to chemotherapy, surgery and minimally invasive procedures such as radiofrequency ablation. External beam radiation therapy has a limited role in the treatment of liver malignancy, mainly due to the substantial risk of radiation-induced liver disease. Transarterial chemoembolisation is contraindicated in patients with portal vein thrombosis or advanced liver disease. Selective internal radiation therapy using yttrium-90 microspheres has emerged as a suitable treatment of liver tumours. In this review we discuss the principles behind this treatment, the process of patient selection, and the method of dose calculation and administration. We also highlight possible adverse effects and review the literature for data on response assessment and long-term outcome.
Introduction
The liver is a common site of malignant disease with hepatocellular carcinoma (HCC) and liver metastases accounting for the majority of liver malignancies.
As a site of metastatic disease, the liver is the exemplary organ of Paget's ''seed and soil'' hypothesis [1] . The liver's receptor-rich sinusoid system provides the necessary mechanism for lodging of the metastatic ''seed'' cells [2, 3] and its rich blood supply helps to create an environment conducive to clonal expansion of the metastatic ''seeds''. Metastatic disease to the liver outnumbers primary liver malignancy by ten to one [4] and approximately 50 % of liver metastases originate from a primary colorectal cancer [5] . The outcome of untreated colorectal liver metastases (CLM) is dismal with a 5-year survival rate of 8 % [6] .
Cirrhosis, with the resultant destruction of normal liver architecture, is said to confer relative protection against liver metastases [7, 8] . However, factors leading to cirrhosis significantly increase the patients' risk of developing HCC, which is the sixth commonest cancer worldwide [9] . Recent years have seen an increase in HCC incidence particularly in North America and Europe [10, 11] . The prognosis of HCC is abysmal, with a 1-year survival rate of less than 50 % [10] and a 5-year survival rate of 15 % [12] .
Treatment options
Conventional treatment options for both primary and secondary liver malignancies are confined to chemotherapy, surgery and minimally invasive procedures such as radiofrequency ablation which targets a few small lesions. External beam radiation therapy has a limited role in the treatment of liver malignancy, mainly due to the substantial risk of radiation-induced liver disease at radiation doses (30-40 Gy) [13] [14] [15] significantly below tumoricidal doses (70 Gy in radiation-only therapy, 50 Gy when combined with chemotherapy) [16, 17] .
In HCC, surgical resection and liver transplantation offer the best curative potential, with reported 5-year recurrence-free survival rates of up to 90 % [18] , but these approaches only benefit patients with limited or early stage disease; indeed, only 20 % of patients with HCC are considered surgical candidates [19] . The remaining patients present with advanced disease and are not amenable to surgery. Systemic chemotherapy with sorafenib, an oral multi-tyrosine kinase inhibitor, has given disappointing results, with an 8 % response rate and 10.7 months of median overall survival compared to 7.9 months for patients receiving placebo [20] .
Surgical resection offers the best chance of survival in CLM too [21, 22] . However, only 10-15 % of cases are resectable at diagnosis [23] . Neoadjuvant chemotherapy is effective in downstaging metastatic lesions, rendering onethird of unresectable cases amenable to surgery [24] [25] [26] [27] . However, the response rate to chemotherapy is between 31 and 56 % [28, 29] . Furthermore, even in patients who are treated surgically the prognosis remains poor, with a 5-year survival rate of 38 % [30] .
A variety of minimally invasive procedures have been put forward as potential alternative treatments of focal liver lesions, including percutaneous ethanol injection, cryoablation and microwave/radiofrequency ablation (RFA); RFA is currently the standard of care in ablative therapy [31] . The main limitation of this technique is that effective ablation of tumour beyond 3 cm can be difficult to achieve [32] . The location of the tumour may also dictate the feasibility of the technique. Lesions located near blood vessels can be difficult to ablate due to the ''heat sink'' effect [33] , while ablation of lesions near the hilum, gallbladder, gastrointestinal (GI) tract and skin surface carries a risk of collateral damage to these structures [34] . In addition, since only lesions visible on imaging can be targeted with these techniques, there is a potential for recurrence from microscopic foci. Available data on this theoretical risk are equivocal. It has been shown that, compared to surgical resection, RFA has a higher recurrence rate and a lower survival rate [35] . Conversely, Chen et al. [36] , Hong et al. [37] and Montorsi et al. [38] reported similar survival rates between RFA and surgical resection.
It is clear that there is a therapeutic gap between surgical resection, systemic therapy and targeted minimally invasive procedures such as RFA and cryoablation. The realisation that both primary and metastatic liver lesions derive 95 % of their blood supply from the hepatic artery (whereas normal liver parenchyma receives 25 % of its blood supply from the hepatic artery) [39] prompted the development of loco-regional transarterial embolisation treatment of selected liver lobes or segments, which may bridge this gap. This treatment can be performed using chemotherapeutic agents and is known as transarterial chemoembolisation (TACE). [45] . Apart from chemotherapeutic agents, radioactive substances can also be used for transarterial loco-regional treatment of the liver, in an approach termed selective internal radiation therapy (SIRT).
Selective internal radiation therapy
The ideal SIRT agent would be one that preferentially targets the tumour tissue and has little effect on the normal liver parenchyma or other organ systems. Such a therapeutic agent should also have limited radiation range, therefore minimising radiation protection issues. 131 I is also a gamma emitter with a principal gamma photon energy of 364 keV, necessitating radioprotection constraints. In addition, 131 I-lipiodol production is currently produced only in France. These factors limit the widespread use of 131 I-lipiodol. Compared to 131 I -lipiodol, the yttrium-90 ( 90 Y) microsphere is a near-perfect SIRT agent as 90 Y is a pure beta emitter with a half-life of 64.2 h, decaying into stable zirconium-90. The maximum beta-particle energy is 2.27 MeV (mean energy 0.93 MeV) and the maximum range in tissue is 11 mm (mean 2.5 mm), thus limiting radiation damage to a small region around the uptake site. In addition, although 90 Y emits no gamma radiation, Bremsstrahlung photons are emitted when the beta particles interact with tissues, thus allowing post-procedural imaging to evaluate distribution of the therapeutic dose.
In 90 Y-SIRT, 90 Y-labelled microscopic resin or glass beads are delivered through intra-arterial infusion of selected branches of the hepatic artery by selective angiocatheterisation. Once injected, the radiolabelled microspheres lodge within the tumour vascular bed permanently [50, 51] and are neither metabolised nor excreted. It has been shown that 90 Y-microspheres preferentially accumulated at the edge of the tumours and were able to deliver activity upward of 100 Gy to tumour tissues [50] .
The tumoricidal effect of SIRT, and radiation therapy in general, occurs as a result of DNA double strand breaks and activation of other cellular pathways [52] . In contrast to TACE, SIRT with 90 Y-microspheres is not designed to induce ischaemia. In fact, effective radiation-induced cell death depends on the generation of free radicals, which is in turn dependent on the presence of oxygen [53, 54] .
Selective internal radiation therapy with Table 1 compares the physical characteristics of these two products.
Patient selection and contraindications
Patients who benefit most from 90 Y-microspheres are those with liver predominant primary or metastatic disease who are not eligible for curative surgery. The decision to opt for 90 Y-microsphere therapy should result from multidisciplinary discussion between experts from medical oncology, radiation oncology, surgery, interventional radiology and nuclear medicine, while also taking into account the patient's preference. As 90 Y-microsphere therapy has not been demonstrated to be curative, the patient's disease status and eligibility for curative surgery should be ascertained on triplephase CT or MRI with gadolinium contrast. The presence and extent of extrahepatic disease, which may ultimately determine the prognosis regardless of the treatment of the liver disease, should also be determined. Although PVT is also listed as a contraindication by both the REBOC group and in the EANM guideline, there is mounting evidence that PVT, even when the main trunk is involved, is not an absolute contraindication to SIRT (please see below section on ''Special circumstances''). Indeed, PVT is no longer listed as a contraindication in more up-to-date patient selection guidelines such as the one produced by Coldwell et al. [61] .
Effects of cumulative radiation dose from SIRT and previous radiotherapy have not been documented and prior radiotherapy is thus a relative contraindication to SIRT. Patients whose life expectancy is less than 1 month are also considered unsuitable for SIRT for radiation protection reasons.
Patient work-up
In addition to multidisciplinary discussion, patients being considered for 90 
Visceral angiography
The purpose of pre-treatment visceral angiography is threefold. First, the arterial blood supply of the liver needs to be mapped. The classic hepatic arterial pattern is found in only Y-microspheres and is a contraindication to such therapy. This can be demonstrated on pre-treatment angiography.
Second, the arterial supply of the gastroduodenal territory may arise from the hepatic artery or the territory may receive collaterals from the hepatic arterial tree (Fig. 1a) . Inadvertent delivery of 90 Y-microspheres into these vessels can cause GI ulceration and pancreatitis [63, 64] . Thus, routine pre-treatment embolisation of the gastroduodenal artery, right gastric artery and other collateral vessels is recommended [65] . As these vessels can revascularise and new collaterals can rapidly form [66] (Fig. 1b) , it is also recommended that embolisation be performed close to the actual SIRT treatment date (e.g. within 1 week) and a check angiogram should be done just prior to infusion of 90 Y-microspheres to exclude revascularisation.
Finally, during pre-treatment angiography, 75-150 MBq of 99m TC-MAA is infused at the same rate planned for the 90 Y-microsphere treatment with the catheter also in the same position as for the planned SIRT procedure to facilitate calculation of hepatopulmonary shunt.
Hepatopulmonary shunt
The individual 90 Y-microspheres can be as small as 20 lm and can traverse the hepatic sinusoids into the right heart and pulmonary circulation. In addition, arteriovenous malformations, either congenital or related to tumours, cause blood to bypass the capillary bed and be shunted from hepatic arterial tree to systemic venous circulation and subsequently the lungs. The amount of shunting, the lung shunt fraction (LSF), is defined as lungcounts lung þ liver counts on scintigraphy after intra-arterial infusion of 99m Tc-MAA as described above. Before injection of 99m Tc-MAA, attenuation correction with 99m Tc or cobalt-57 flood source should be performed to avoid overestimation of the LSF [67] . Administration of 90 Y-microspheres in the presence of a significant shunt carries a risk of inducing radiation pneumonitis. Radioembolisation is therefore not recommended in the presence of a LSF above 20 % (Fig. 2) . It is estimated that 20 % of patients with HCC and 5 % of patients with CLM have a LSF [20 % [68] . Tumour thrombosis of the hepatic vein increases the likelihood of significant lung shunt [69] .
Dosimetry
For glass microspheres, the prescribed dose is calculated as follows:
where A is the prescribed dose in Gy, D the nominal target dose, typically 100-120 Gy for the liver; and M is the mass of the planning target volume (i.e. the whole liver or the The final prescribed dose is adjusted according to the amount of lung shunt via two methods. First, the final prescribed dose can be adjusted so that the cumulative lung dose remains below 30 Gy, which is the upper limit recommended by REBOC [59] . Cumulative lung dose can be calculated according to the following equation:
where D lung is the cumulative lung dose in Gy, A total is the total prescribed activity in GBq, LSF is the lung shunt fraction, and M lung is the mass of the lungs, assumed to be 1,000 g. Tc MAA lung shunt study in a patient with colorectal liver metastases. There is intense and heterogeneous uptake within the enlarged liver due to extensive tumour replacement (green dotted line). Markedly increased activity is also seen in both lungs (purple dotted lines). The LSF was 32 %. Therefore, this patient did not receive 90 Y-microspheres due to the high risk of radiation pneumonitis (colour figure online) Alternatively, the final prescribed dose can be empirically adjusted according to Table 2 .
During the delivery of 90 Y-microspheres, it is recommended that flow of the catheterised hepatic arterial branch be regularly checked by injection of contrast media. If the antegrade arterial flow has slowed down then the infusion of 90 Y-microspheres should be terminated, even if the prescribed dose has not been fully delivered [59] .
Adverse reactions and complications
Intra-arterial administration of 90 Y-microspheres is generally well tolerated by patients [70] . Fatigue, nausea, vomiting, low-grade pyrexia, and abdominal discomfort are by far the commonest adverse reactions, reported in 20-50 % of patients, and they tend to be self-limiting, usually resolving within a few hours [70] [71] [72] [73] . At our institution, we have sometimes used a tapering dose of steroids to alleviate these symptoms.
Inadvertent delivery of microspheres to non-target organs can cause complications due to radiation (Fig. 3) . Excessive radiation dose to the lungs can cause radiation pneumonitis [74] which is a rare event when the proper dosimetric procedure is followed [70] , although a recent study questioned the validity of the conventional lung dosimetry method in predicting radiation pneumonitis [75] . The literature on 90 Y-microsphere SIRT-related GI ulceration is limited but this condition has been reported to occur in 0-11 % of patients [70, 76] . Pre-treatment embolisation of collateral vessels serves to reduce the likelihood of GI ulceration due to reflux of 90 Y-microspheres into extrahepatic arteries. However, new collateral formation is common and Abdelmaksoud et al. [66] showed that despite re-embolisation immediately before delivery of 90 Y-microspheres, 7 % of patients still developed gastroduodenal ulceration. Reversible gastritis and duodenitis have also been reported in the absence of extrahepatic microsphere deposition [77] . Although most safety and toxicity studies demonstrate only mild-to-moderate GI ulceration after 90 Y-microsphere SIRT, this entity can be difficult to treat. In isolated cases, GI ulcerations persist up to 12 months post-SIRT [78] . Post-treatment Bremsstrahlung SPECT/CT may help to predict the likelihood of GI ulceration [79] . At our institution, we tend to commence patients on a proton pump inhibitor 1 week prior to 90 Y-microsphere treatment and continue this drug for 4 weeks after treatment to prevent this complication.
As a large volume of blood is circulated through the liver, radiation effects on the various components of blood is unavoidable. Pancytopenia was observed in one of the earliest studies of 90 Y-microspheres [58] but has not been reported since. Isolated cases of transient thrombocytopenia following 90 Y-microsphere SIRT have also been reported [80, 81] . Lymphopenia is a common complication observed by Carr et al. [82, 83] in a large proportion of patients who underwent 90 Y-microsphere SIRT; the absence of lymphocyte count recovery was associated with poor survival [83] .
One of the most serious complications after 90 Ymicrosphere therapy is radioembolisation-induced liver disease (REILD), i.e. post-treatment liver failure that is not attributable to disease progression. Veno-occlusive disease has been shown to be the histological manifestation [84] . In the largest cohort to date, consisting of 515 patients with primary and metastatic liver malignancies, Kennedy et al. [85] reported a 4 % incidence of REILD after resin 90 Y-microsphere SIRT in patients with unresectable liver tumours. The same paper also reported a strong correlation between the rate of REILD and the empirical dosimetry method. Although it has been suggested that REILD does not develop below the dose of 1.5 GBq with glass 90 Y-microspheres [86] , in a cohort consisting of 291 patients with HCC, Salem et al. [73] reported grade 3/4 bilirubin/aspartate transaminase toxicity in 19 % of patients. This toxicity is associated with previous treatment with chemotherapy and whole-liver 90 Y-microsphere treatment [84] , and treating the two lobes of liver sequentially a few weeks apart, rather than treating the whole liver in one procedure, may help to mitigate it [87] . Paradoxically, a more recent study examining the role of a modified dosimetry regime in preventing REILD [88] found that in patients with cirrhosis, selective liver radioembolisation (instead of whole-liver treatment) was associated with increased incidence of REILD. Most cases that developed REILD in this study received radiation upwards of 0.8 GBq. The authors suggested that one explanation for finding might be a relative increase in radiation per treated volume in selective treatment. The same study also found cirrhosis, previous liver insult (including systemic chemotherapy), small liver and abnormal pre-treatment bilirubin to be associated with increased risk of REILD.
At our institution, we have shown a low rate of adverse effects in patients who were carefully selected for SIRT. Out of a small cohort of 21 patients, four developed reversible adverse effects (two cases of radiation hepatitis, and one case each of cholecystitis and peptic ulceration) [89] . The rate of adverse effects in our current cohort of more than 200 cases is being analysed for publication.
Response assessment and prediction
Although, conventionally, tumour response assessment is most commonly performed using size-based criteria (WHO [90] , RECIST [91] and RECIST 1.1 [92] ), malignant lesions often do not demonstrate a size change even when there is a histological response [93] .
Alternative methods of assessing treatment response include FDG ( 18 F-fluorodeoxyglucose) PET, CT attenuation and diffusion-weighted MRI. A reduction of metabolic activity on FDG PET (Fig. 4) is more sensitive in detecting responding lesions than size-based CT criteria in patients treated with 90 Y-microsphere SIRT [94] [95] [96] . As 90 Y-microsphere SIRT induces necrosis within treated tumours [51, 97] , a decrease in CT attenuation and diminished enhancement of tumours have been used to assess response (Fig. 5 ). These changes have been shown to correlate with FDG PET metabolic response better than size reduction [98] [99] [100] . Normalisation of diffusion on diffusion-weighted MRI has also been suggested as another method of detecting response when there is no change in size [100] . As the delivery of 90 Y-microspheres to the tumour depends on the vascularity of the tumour, it stands to reason that the degree of tumour perfusion may be correlated with treatment response. However, the utility of pretreatment 99m Tc-MAA study in predicting response and outcome is controversial. While some authors have shown that quantitative assessment of 99m Tc-MAA tumoral uptake on SPECT/CT performed as part of dosimetry calculation can predict response, time-to-progression and overall survival [101, 102] , others have found no correlation between tumoral MAA uptake and response rate [103] . More recently, textural features on pre-treatment triple-phase CT have been shown to predict response and survival in patients with hepatic malignancy [104] . These methods await confirmation and may allow for better patient selection in the future.
Clinical use
The last decade has seen an explosion of studies investigating the clinical efficacy of 90 Y-microspheres, with more than 70 papers published on this topic (Tables 3, 4, 5). Despite this wealth of literature, it is difficult to objectively assess the effectiveness of 90 Y-microspheres as a locoregional treatment for hepatic malignancy for the following reasons. First, most of the published findings are derived from retrospective data, describing single-centre experiences. Patient cohorts in these studies tended to be heterogeneous, with vastly different performance status and liver function. Most would have also undergone multiple lines of treatment prior to being considered for 90 Y-microsphere SIRT as salvage therapy. This limits the inference that can be drawn when comparing the response rate and survival benefit of 90 Y-microspheres to other treatment options. Second, the methods for assessing response, reported in the literature, also vary widely, with some studies using size-based criteria such as WHO and RECIST and others using criteria that take into account CT attenuation (modified RECIST [105] and EASL [106] ) or criteria based on metabolic response on PET. As reported by Salem's group [107] [108] [109] and Shim et al. [110] , the response rates derived from these methods differ significantly, again limiting the way the existing literature can be interpreted. Nevertheless, 90 Y-microsphere treatment has been shown to have an emerging role in the management of a group of patients who have exhausted other treatment options.
Response rate
Regardless of the response assessment method employed, 90 Y-microspheres appear to have a good response rate, in the region of 30 % in HCC and 40 % in CLM (but as high as 90 % when assessed with metabolic activity on FDG PET [71] ; see Tables 3, 4, 5) .
In a small proportion of patients, 90 Y-microsphere SIRT has led to sufficient downstaging of tumour to allow resection [111] [112] [113] or RFA [114] .
Long-term outcome
Comparative studies suggest that 90 Y-microspheres can significantly prolong survival. D'Avola et al. [115] showed that the median survival in HCC patients who have undergone 90 Y-SIRT is double that of those receiving conservative management (16 vs 8 months); similarly, in metastatic liver disease from other primary cancers, Y-microspheres was 12 months compared to 6.3 months on standard care [116] . When compared to other intra-arterial treatments for HCC, 90 Ymicrosphere SIRT demonstrates equivalent efficacy to TACE [117, 118] but is associated with a slightly better quality of life [119] .
More uncommonly, radiation lobectomy may develop after 90 Y-microsphere SIRT treatment. In this condition, first described by Jakobs et al. [120] in 2008, patients show a reduction of ipsilateral hepatic lobar volume, contralateral lobar hypertrophy, liver fibrosis and in some cases portal hypertension. It has subsequently been shown to be associated with higher response rate and survival advantage in patients with primary liver cancers [121] , with a 46 % 5-year survival rate being reported in HCC patients.
A significant difference in outcome has been reported between patients having different clinical statuses. Patients who have a good performance status, low tumour burden and relatively preserved liver functions benefited the most from 90 Y-microspheres [73, 82, [122] [123] [124] [125] [126] [127] [128] . Furthermore, in a meta-analysis that included many of the studies included in Tables 3, 4 , 5, Vente et al. [129] found that in patients with CLM, use of 90 Y-microspheres as first-line therapy provided significantly better disease control (i.e. ''partial response'' and ''stable disease'') than in the salvage setting. Thus, there is an argument for treating with 90 Y-microspheres much earlier in the disease process rather than using 90 Y-microspheres as a salvage therapy, as is done in current practice. To this end, several prospective trials [130] [131] [132] are under way which aim to establish the efficacy of 90 Y-microspheres as a first-line therapy.
Special circumstances
Some comorbidities can increase the treatment risk of patients undergoing 90 Y-microsphere SIRT. Portal vein thrombosis is a common complication in patients with primary liver malignancy. While the liver has a dual blood supply via the portal vein and hepatic artery, thrombosis of the portal vein would leave the area of liver it supplies relying more heavily on arterial circulation. Arterial radioembolisation with 90 Y-microspheres is therefore conventionally thought to be contraindicated [59, 60] . However, several authors have demonstrated the feasibility and relative safety of 90 Y-microsphere treatment in the presence of PVT [133] [134] [135] .
Another common complication in patients with hepatic malignancy is biliary obstruction. Few reports exist on the safety and efficacy of 90 Y-microsphere SIRT in this setting but in a cohort of 12 patients with malignant biliary obstruction at a lobar or segmental level (but normal serum bilirubin) Gaba et al. [136] found 90 Y-microsphere SIRT to be safe with no biliary complication after treatment.
Conclusion
90 Y-microsphere SIRT is a promising technique in the treatment of hepatic malignancy. Both the devices and the technique have been refined over the last four decades to the point where 90 Y-microsphere SIRT is not only feasible and safe, but also has a better toxicity profile, response rate and outcome than systemic therapy. While a wealth of literature has already been published on 90 Y-microsphere SIRT, there is a need to establish its efficacy against other therapeutic options, especially in early stage disease. The prospective, randomised-controlled trials that are currently being conducted will hopefully be able to provide guidance in this regard. 
